Antiproliferative effects of mitochondria-targeted cationic antioxidants and analogs: Role of mitochondrial bioenergetics and energy-sensing mechanism

Cancer Letters

Volumn 365, Issue 1, 2015, Pages 96-106

  Cheng, Gang ^a   Zielonka, Jacek ^a   McAllister, Donna ^a   Hardy, Micael ^b   Ouari, Olivier ^b   Joseph, Joy ^a   Dwinell, Michael B ^c   Kalyanaraman, Balaraman ^a  

^a FREE RADICAL RESEARCH CENTER   (United States)

^b AIX MARSEILLE UNIV   (France)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

2 DG; Antioxidant; Mitochondria; ROS; Superoxide; Tumor cell proliferation

Indexed keywords

ACETAMIDE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIOXIDANT DERIVATIVE; CITRIC ACID; DEOXYGLUCOSE; MITOCHONDRIA TARGETED CATIONIC CARBOXYPROXYL NITROXIDE; NITROXIDE DERIVATIVE; SUPEROXIDE; SUPEROXIDE DISMUTASE; SYNTHETIC CATIONIC ACETAMIDE DERIVATIVE; UNCLASSIFIED DRUG; AMINE OXIDE; CATION; MITO-CARBOXY PROXYL; ORGANOPHOSPHORUS COMPOUND;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BIOENERGY; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; GLYCOLYSIS; HUMAN; HUMAN CELL; MITOCHONDRION; PANCREAS CANCER; PRIORITY JOURNAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; ENERGY METABOLISM; MCF 7 CELL LINE; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; TIME;

VASCONCELLEA CANDICANS;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CATIONS; CELL PROLIFERATION; CYCLIC N-OXIDES; DEOXYGLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENERGY METABOLISM; GLYCOLYSIS; HUMANS; MCF-7 CELLS; MITOCHONDRIA; NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; SUPEROXIDES; TIME FACTORS;

EID: 84930823628     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.05.016     Document Type: Article

References (45)

1. Fruehauf J.P., Meyskens F.L. Reactive oxygen species: a breath of life or death?. Clin. Cancer Res 2007, 13:789-794. 10.1158/1078-0432.CCR-06-2082.
2. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov 2009, 8:579-591. 10.1038/nrd2803.
3. Behrend L., Henderson G., Zwacka R.M. Reactive oxygen species in oncogenic transformation. Biochem. Soc. Trans 2003, 31:1441-1444.
4. Shin S.Y., Lee J.M., Lee M.S., Jung H., Lee Y.H. Targeting cancer cells via the reactive oxygen species-mediated unfolded protein response with a novel synthetic polyphenol conjugate. Clin. Cancer Res 2014, 20:4302-4313. 10.1158/1078-0432.
5. Liou G.-Y., Storz P. Reactive oxygen species in cancer. Free Radic. Res 2010, 44:479-496. 10.3109/10715761003667554.
6. St.Clair D.K., Jordan J.A., Wan X.S., Gairola C.G. Protective role of manganese superoxide dismutase against cigarette smoke-induced cytotoxicity. J. Toxicol. Environ. Health 1994, 43:239-249.
7. Sayin V.I., Ibrahim M.X., Larsson E., Nilsson J.A., Lindahl P., Bergo M.O. Antioxidants accelerate lung cancer progression in mice. Sci. Transl. Med 2014, 6(221):221ra15. 10.1126/scitranslmed.3007653.
8. Block K., Gorin Y. Aiding and abetting roles of NOX oxidases in cellular transformation. Nat. Rev. Cancer 2012, 12:627-637. 10.1038/nrc3339.
9. Sanchez-Sanchez B., Gutiérrez-Herrero S., López-Ruano G., Prieto-Bermejo R., Romo-González M., Llanillo M., et al. NADPH oxidases as therapeutic targets in chronic myelogenous leukemia. Clin. Cancer Res 2014, 20:4014-4025. 10.1158/1078-0432.
10. Cheng G., Zielonka J., Dranka B.P., McAllister D., Mackinnon A.C., Joseph J., et al. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res 2012, 72:2634-2644. 10.1158/0008-5472.
11. Cheng G., Zielonka J., McAllister D.M., Mackinnon A.C., Joseph J., Dwinell M.B., et al. Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death. BMC Cancer 2013, 13:285. 10.1186/1471-2407-13-285.
12. Starenki D., Park J.I. Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo. J. Clin. Endocrinol. Metab 1529, 98:40-2013. 10.1210/jc.2012-3671.
13. Jain M., Rivera S., Monclus E.A., Synenki L., Zirk A., Eisenbart J., et al. Mitochondrial reactive oxygen species regulate transforming growth factor-β signaling. J. Biol. Chem 2013, 288:770-777. 10.1074/jbc.M112.431973.
14. Weinberg F., Hamanaka R., Wheaton W.W., Weinberg S., Joseph J., Lopez M., et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:8788-8793. 10.1073/pnas.1003428107.
15. Chalier F., Tordo P. 5-Diisopropoxyphosphoryl-5-methyl-1-pyrroline N-oxide, DIPPMPO, a crystalline analog of the nitrone DEPMPO: synthesis and spin trapping properties. J. Chem. Soc. Perk. T2 2002, 12:2110-2117.
16. Hardy M., Poulhés F., Rizzato E., Rockenbauer A., Banaszak K., Karoui H., et al. Mitochondria-targeted spin traps: synthesis, superoxide spin trapping, and mitochondrial uptake. Chem. Res. Toxicol 2014, 27:1155-1165. 10.1021/tx500032e.
17. Dhanasekaran A., Kotamraju S., Karunakaran C., Kalivendi S.V., Thomas S., Joseph J., et al. Mitochondria superoxide dismutase mimetic inhibits peroxide-induced oxidative damage and apoptosis: role of mitochondrial superoxide. Free Radic. Biol. Med 2005, 39:567-583. 10.1016/j.freeradbiomed.2005.04.016.
18. Dickey J.S., Gonzalez Y., Aryal B., Mog S., Nakamura A.J., Redon C.E., et al. Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model. PLoS ONE 2013, 8:e70575. 10.1371/journal.pone.0070575.
19. Zimmerman N.P., Roy I., Hauser A.D., Wilson J.M., Williams C.L., Dwinell M.B. Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells. Mol. Carcinog 2015, 54:203-215. 10.1002/mc.22091.
20. Cheng G., Zielonka J., McAllister D., Tsai S., Dwinell M.B., Kalyanaraman B. Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. Br. J. Cancer 2014, 111:85-93. 10.1038/bjc.2014.272.
21. Dong L.F., Freeman R., Liu J., Zobalova R., Marin-Hernandez A., Stantic M., et al. Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II. Clin. Cancer Res 1593, 15:600-2009. 10.1158/1078-0432.CCR-08-2439.
22. Dranka B.P., Hill B.G., Darley-Usmar V.M. Mitochondrial reserve capacity in endothelial cells: the impact of nitric oxide and reactive oxygen species. Free Radic. Biol. Med 2010, 48:905-914. 10.1016/j.freeradbiomed.2010.01.015.
23. Dranka B.P., Zielonka J., Kanthasamy A.G., Kalyanaraman B. Alterations in bioenergetic function induced by Parkinson's disease mimetic compounds: lack of correlation with superoxide generation. J. Neurochem 2012, 122:941-951. 10.1111/j.1471-4159.2012.07836.x.
24. Franken N.A., Rodermond H.M., Stap J., Haveman J., van Bree C. Clonogenic assay of cells in vitro. Nat. Protoc 2006, 1:2315-2319. 10.1038/nprot.2006.339.
25. Balcke G.U., Kolle S.N., Kamp H., Bethan B., Looser R., Wagner S., et al. Linking energy metabolism to dysfunctions in mitochondrial respiration-a metabolomics in vitro approach. Toxicol. Lett 2011, 203:200-209. 10.1016/j.toxlet.2011.03.013.
26. Nicholls D.G., Darley-Usmar V.M., Wu M., Jensen P.B., Rogers G.W., Ferrick D.A. Bioenergetic profile experiment using C2C12 myoblast cells. J. Vis. Exp 2010, 46. 2511 [pii]. 10.3791/2511.
27. Icard P., Poulain L., Lincet H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim. Biophys. Acta 1825, 111-6:2012. 10.1016/j.bbcan.2011.10.007.
28. Nadakavukaren K.K., Nadakavukaren J.J., Chen L.B. Increased rhodamine 123 uptake by carcinoma cells. Cancer Res 1985, 45:6093-6099.
29. Kurtoglu M., Lampidis T.J. From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors. Mol. Nutr. Food Res 2009, 53:68-75. 10.1002/mnfr.200700457.
30. Smith R.A., Hartley R.C., Murphy M.P. Mitochondria-targeted small molecule therapeutics and probes. Antioxid. Redox Signal 2011, 15:3021-3038. 10.1089/ars.2011.3969.
31. Dong L.F., Jameson V.J., Tilly D., Cerny J., Mahdavian E., Marín-Hernández A., et al. Mitochondrial targeting of vitamin E succinate enhances its pro-apoptotic and anti-cancer activity via mitochondrial complex II. J. Biol. Chem 2011, 286:3717-3728. 10.1074/jbc.M110.186643.
32. Reddy C.A., Somepalli V., Golakoti T., Kanugula A.K., Karnewar S., Rajendiran K., et al. Mitochondrial-targeted curcuminoids: a strategy to enhance bioavailability and anticancer efficacy of curcumin. PLoS ONE 2014, 9:e89351. 10.1371/journal.pone.0089351.
33. Rodríguez-Enríquez S., Gallardo-Pérez J.C., Hernández-Reséndiz I., Marín-Hernández A., Pacheco-Velázquez S.C., López-Ramírez S.Y., et al. Canonical and new generation anticancer drugs also target energy metabolism. Arch. Toxicol 2014, 88:1327-1350. 10.1007/s00204.
34. Phan M.L., Yeung S.C., Lee M.H. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol. Med 2014, 11:1-19.
35. Chen S., Zhu X., Lai X., Xiao T., Wen A., Zhang J. Combined cancer therapy with non-conventional drugs: all roads lead to AMPK. Mini Rev. Med. Chem 2014, 14:642-654. 10.2174/1389557514666140820104444.
36. Kuhajda F.P. AMP-activated protein kinase and human cancer: cancer metabolism revisited. Int. J. Obes. (Lond.) 2008, 32(Suppl. 4):S36-S41. 10.1038/ijo.2008.121.
37. Hardie D.G. AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. Curr. Opin. Cell Biol 2014, 33C:1-7.
38. Emerling B.M., Weinberg F., Snyder C., Burgess Z., Mutlu G.M., Viollet B., et al. Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. Free Radic. Biol. Med 2009, 46:1386-1391.
39. Yung M.M., Chan D.W., Liu V.W., Yao K.M., Ngan H.Y. Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade. BMC Cancer 2013, 13:327. 10.1016/j.freeradbiomed.2009.02.019.
40. Cunniff B., Benson K., Stumpff J., Newick K., Held P., Taatjes D., et al. Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells. J. Cell. Physiol 2013, 228:835-845. 10.1002/jcp.24232.
41. Cook J.A., Gius D., Wink D.A., Krishna M.C., Russo A., Mitchell J.B. Oxidative stress, redox, and the tumor microenvironment. Semin. Radiat. Oncol 2004, 14:259-266. 10.1016/j.semradonc.2004.04.001.
42. Glasauer A., Chandel N.S. Targeting antioxidants for cancer therapy. Biochem. Pharmacol 2014, 92:90-101. 10.1016/j.bcp.2014.07.017.
43. Le A., Stine Z.E., Nguyen C., Afzal J., Sun P., Hamaker M., et al. Tumorigenicity of hypoxic respiring cancer cells revealed by a hypoxia-cell cycle dual reporter. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:12486-12491. 10.1073/pnas.1402012111.
44. Mukhopadhyay P., Horváth B., Zsengellér Z., Zielonka J., Tanchian G., Holovac E., et al. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radic. Biol. Med 2012, 52:497-506. 10.1016/j.freeradbiomed.2011.
45. Ghosh A., Kanthasamy A., Joseph J., Anantharam V., Srivastava P., Dranka B.P., et al. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease. J. Neuroinflammation 2012, 9:241. 10.1186/1742-2094-9-241.